The World Health Organization issues a public call for individual patients data on rifampicin-resistant and multidrug-resistant TB treatment outcomes.
01 August 2019 | Geneva: The World Health Organization (WHO) is initiating the development of new guidelines on the treatment of drug-resistant TB following new evidence made available this year. The last evidence-based guidance for the treatment of rifampicin-resistant and multidrug-resistant TB (MDR/RR-TB) was published by WHO in December 2018.
Ahead of the guidelines development group meeting, planned in November 2019, WHO will commission reviews of relevant evidence on the effect of different treatment regimens on patient outcomes.
To enable this process, WHO is issuing a public call, appealing to industry, researchers, national TB programmes and other agencies to provide suitable datasets.
The request is for individual patients’ data on MDR/RR-TB patients with the following specifics:
1. use of bedaquiline for longer than 6 months as a part of longer treatment regimens
2. use of all oral bedaquiline-containing shorter regimens of 9-12 months duration
3. concurrent use of bedaquiline and delamanid
4. use of bedaquiline-containing regimens in pregnant women
The data will be essential to facilitate the process of WHO policy updates. Please let us know if you have data to contribute by 10 August 2019.
The completed dataset in the requested format should be submitted with the signed data sharing agreement by 15 August 2019.
More information on the requirements of the datasets, variables, the process, deadlines and contacts is available here.